Autonomous Reef Monitoring Structures (ARMS) as a tool to uncover neglected marine biodiversity: two new Solenogastres (Mollusca, Aplacophora) from the Gulf of Mexico.

Solenogastres is a group of mollusks with evolutionary and ecological importance. Nevertheless, their diversity is underestimated and knowledge about the distribution of the approximately 300 formally described species is limited. Factors that contribute to this include their small size and frequent misidentification by non-specialists.

Pulmonary Embolism Response Teams-Evidence of Benefits? A Systematic Review and Meta-Analysis.

Venous thromboembolisms constitute a major cause of morbidity and mortality with 60,000 to 100,000 deaths attributed to pulmonary embolism in the US annually. Both clinical presentations and treatment strategies can vary greatly, and the selection of an appropriate therapeutic strategy is often provider specific. A pulmonary embolism response team (PERT) offers a multidisciplinary approach to clinical decision making and the management of high-risk pulmonary emboli.

A Protocol for a Mixed Methods, Single-Arm, Hybrid Effectiveness-Implementation Trial Evaluating a 12-week Yoga Intervention Delivered by Videoconference for Young Adults Diagnosed With Cancer.

Background: Cancer among young adults (18-39 years) is relatively rare, but remains a leading cause of disability, morbidity, and mortality. Identifying strategies to support young adults' health following a diagnosis of cancer is important. Yoga may enhance health and could be delivered by videoconference.

Safety of enoxaparin in patients implanted with continuous flow left ventricular assist devices.

Background: The objective of this study is to determine the incidence of major bleeding events in patients implanted with continuous flow left ventricular assist devices (CF-LVADs) bridged with enoxaparin (LMWH) compared to intravenous unfractionated heparin (IV UFH) for a subtherapeutic INR on warfarin.

Methods: A single-center, retrospective, cohort study was conducted including patients with CF-LVADs implanted between January 1, 2012 and July 1, 2020 who received at least one inpatient dose or outpatient prescription for LMWH or IV UFH at least 60 days after CF-LVAD implantation. The primary endpoint was the incidence of major bleeding.